查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1888676

医药中心和病患准入支援服务市场规模、份额和趋势分析报告：按服务类型、产品类型、地区和细分市场预测（2025-2033 年）

Pharma Hub And Patient Access Support Service Market Size, Share & Trends Analysis Report By Service Type, By Service Delivery Type, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

全球医药中心与病患准入支援服务市场摘要

2024 年全球医药中心和病患准入支援服务市场规模估计为 32.4 亿美元，预计到 2033 年将达到 76.3 亿美元。

预计从 2025 年到 2033 年，该行业将以 10.0% 的复合年增长率成长。这一增长是由对各种专科和罕见疾病/孤儿病新药的需求不断增长以及优先构建以患者为中心的生态系统所推动的。

支付方复杂性增加（事先核准、特殊药品清单、索赔拒绝增加）和更严格的成本效益控制正在促使製造商将患者入院活动外包，并从专门的中心提供者那里受益，以进行检验活动和共同支付/费用援助管理。

2021年至2024年间，高成本专科药物和罕见疾病药物的不断涌现，是推动药品中心和病人用药支持服务扩张的主要动力。根据美国食品药物管理局（FDA）统计，2022年共核准了37种新药，其中20种（约占54%）为罕见疾病药物。 2023年，又有55种新药核准，其中28种（占绝大多数）为罕见疾病药物。这些治疗方法价格往往高昂，且需要复杂的保险核准流程。

2022年核准B型血友病的基因疗法HemGenix，每剂费用约350万美元；而2023年核准用于治疗阿兹海默症Rekemvi，每年费用约2.65万美元。这些新药的问世凸显了病患在经济和行政方面面临的日益严峻的挑战，促使製药公司大力投资于数位化平台、福利核实系统、预先核准自动化以及病患援助计画。由此导致的专业化且高成本治疗方法的激增，直接推动了对整合式医疗中心和患者服务解决方案的需求，这些方案旨在简化报销流程、加快治疗启动速度并提高患者的用药依从性。

此外，市场正受到多家公司推行的多项策略措施的推动。例如，2023年11月，Docquity宣布将把其数位化病患服务计画DocquityCare PAP拓展至泰国。该公司致力于透过在泰国推出五个PAP项目，并为250名认证医疗专业人员和约100家註册医院提供支持，从而改善癌症和其他危及生命的疾病患者的护理。

目录

第一章调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场趋势展望
  • 市场动态
  • 商业环境分析
    • 波特五力分析
    • PESTLE分析

4. 医药中心和病人准入支持服务市场：按服务类型分類的估算和趋势分析

  • 按服务类型分類的市场份额变化分析（2024 年和 2033 年）
  • 按服务类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 专案註册
    • 订单处理
    • 应用程式处理
    • 註册方式的便利性（电话、现场、透过入口网站、应用程式）
    • 程式数据
  • 治疗导航员
    • 製程流程图和标准作业程式
    • 节目材料和脚本
    • 护理团队培训
    • 系统测试与最佳化
  • 报销服务/成本降低服务
  • 临床负责人
  • 协调专科药局和配药业务
  • 其他的

5. 医药中心和病人准入支持服务市场：按服务类型分類的估算和趋势分析

  • 按产品类型分類的市占率变化分析（2024 年和 2033 年）
  • 按产品类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 整合服务
  • 独立服务

6. 医药中心和病人准入支持服务市场：区域估算和趋势分析

  • 区域市场概览
  • 区域市场：主要结论
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与公司概况
  • 企业市场分析/企业市场占有率分析（2024）
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Valeris（Formerly PharmaCord）
    • Fortrea
    • AssistRx
    • CareMetx, LLC
    • ConnectiveRx
    • Lash Group
    • McKesson Corporation
    • Engage
    • NS Pharma, Inc.（a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.）
    • Cardinal Health
    • Envoy Health, Inc.
    • EVERSANA
    • United BioSource LLC
    • Mercalis
    • Sciensus
Product Code: GVR-4-68040-278-6

Pharma Hub And Patient Access Support Service Market Summary

The global pharma hub and patient access support service market size was estimated at USD 3.24 billion in 2024 and is projected to reach USD 7.63 billion by 2033, growing at a CAGR of 10.0% from 2025 to 2033. The growth is attributed to the increasing need to administer new medicines for various specialties and rare & orphan diseases, prioritizing creating a patient-centric ecosystem.

Payer-side complexity (prior authorizations, specialty drug formularies, and rising claim denials), and tighter affordability controls have pushed manufacturers to outsource patient onboarding, benefiting verification and copay/cost-assistance management to dedicated hub providers.

The growing launch of high-cost specialty and rare-disease therapies between 2021 and 2024 has become a key driver for the expansion of pharma hubs and patient access support services. According to the U.S. FDA, 37 novel drugs were approved in 2022, of which 20 around 54% were targeted at rare diseases, while in 2023, 55 new drugs were approved, and over half, 28 drugs, were for rare diseases. These therapies often carry exceptionally high price tags and require complex insurance approvals.

Hemgenix, a gene therapy for hemophilia B approved in 2022, was priced at about USD 3.5 million per dose, and Alzheimer's drug Leqembi, approved in 2023, costs around USD 26,500 annually. Such launches highlight the growing financial and administrative barriers for patients, encouraging pharmaceutical companies to invest heavily in digital hub platforms, benefit verification systems, prior authorization automation, and patient support programs. As a result, the increasing number of specialized, high-cost therapies is directly driving demand for integrated pharma hub and patient access support solutions to streamline reimbursement, accelerate therapy initiation, and improve adherence outcomes.

The market is further driven by players undertaking several strategic initiatives. For instance, in November 2023, Docquity announced the expansion of its digitized patient access program, DocquityCare PAP, to Thailand. It launched five PAPs in Thailand, supporting 250 authorized HCPs and around 100 enrolled hospitals to enhance patient care for individuals with cancer and additional life-threatening conditions.

Global Pharma Hub And Patient Access Support Service Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharma HUB and patient access support service market report based on service type, service delivery type, and region:

  • Service Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Program Enrollment
    • Order processing
    • Application processing
    • Ease of enrollment (through phone, face, portal, or app)
    • Program data
  • Treatment Navigators
    • Process flows and standard operating procedures
    • Program literature and scripts
    • Care team training
    • Systems testing and optimization
  • Reimbursement Services/Affordability Services
  • Clinical Educator
  • Coordination of Specialty Pharmacy/Dispensing
  • Others
  • Service Delivery Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Integrated Services
  • Standalone Services
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service Type
    • 1.2.2. Service Delivery Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Launch of Specialty and Rare-Disease Therapies
      • 3.2.1.2. Need to Simplify Patient Enrollment and Therapy Access
      • 3.2.1.3. Growing Emphasis on Patient-Centric Care
      • 3.2.1.4. Increasing Regulatory and Compliance Requirements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High implementation and operational costs
      • 3.2.2.2. Data Privacy and Regulatory Compliance Challenges
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Technology Overview
    • 3.2.6. Case Studies
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape

Chapter 4. Pharma HUB and Patient Access Support Service Market: Service Type Estimates & Trend Analysis

  • 4.1. Service Type Segment Dashboard
  • 4.2. Service Type Market Share Movement Analysis, 2024 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
  • 4.4. Program Enrollment
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Order processing
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Application processing
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
      • 4.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Program data
      • 4.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Treatment Navigators
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Process flows and standard operating procedures
      • 4.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Program literature and scripts
      • 4.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Care team training
      • 4.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Systems testing and optimization
      • 4.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reimbursement Services/Affordability Services
    • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Clinical Educator
    • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Coordination of Specialty Pharmacy/Dispensing
    • 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharma HUB and Patient Access Support Service Market: Delivery Type Estimates & Trend Analysis

  • 5.1. Delivery Segment Dashboard
  • 5.2. Delivery Market Share Movement Analysis, 2024 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Delivery, 2021 to 2033 (USD Million)
  • 5.4. Integrated Services
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Standalone Services
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharma HUB and Patient Access Support Service Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamic
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive insights
      • 6.3.2.4. U.S. Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamic
      • 6.3.3.2. Regulatory framework
      • 6.3.3.3. Competitive insights
      • 6.3.3.4. Canada Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamic
      • 6.3.4.2. Regulatory framework
      • 6.3.4.3. Competitive insights
      • 6.3.4.4. Mexico Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamic
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. Germany Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. UK
      • 6.4.3.1. Key country dynamic
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. UK Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamic
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. France Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamic
      • 6.4.5.2. Regulatory framework
      • 6.4.5.3. Competitive insights
      • 6.4.5.4. Italy Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamic
      • 6.4.6.2. Regulatory framework
      • 6.4.6.3. Competitive insights
      • 6.4.6.4. Spain Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamic
      • 6.4.7.2. Regulatory framework
      • 6.4.7.3. Competitive insights
      • 6.4.7.4. Denmark Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamic
      • 6.4.8.2. Regulatory framework
      • 6.4.8.3. Competitive insights
      • 6.4.8.4. Sweden Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamic
      • 6.4.9.2. Regulatory framework
      • 6.4.9.3. Competitive insights
      • 6.4.9.4. Norway Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamic
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. Japan Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamic
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. China Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamic
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. India Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamic
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. South Korea Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Australia
      • 6.5.6.1. Key country dynamic
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Australia Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamic
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive insights
      • 6.5.7.4. Thailand Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Pharma HUB and Patient Access Support Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamic
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. Brazil Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamic
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. Argentina Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamic
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. South Africa Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamic
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Saudi Arabia Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamic
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive insights
      • 6.7.4.4. UAE Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamic
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive insights
      • 6.7.5.4. Kuwait Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis/Company Market Share Analysis (2024)
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Valeris (Formerly PharmaCord)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Fortrea
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. AssistRx
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. CareMetx, LLC
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. ConnectiveRx
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. Lash Group
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. McKesson Corporation
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Engage
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial performance
      • 7.5.8.3. Product benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial performance
      • 7.5.9.3. Product benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. Cardinal Health
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial performance
      • 7.5.10.3. Product benchmarking
      • 7.5.10.4. Strategic initiatives
    • 7.5.11. Envoy Health, Inc.
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial performance
      • 7.5.11.3. Product benchmarking
      • 7.5.11.4. Strategic initiatives
    • 7.5.12. EVERSANA
      • 7.5.12.1. Overview
      • 7.5.12.2. Financial performance
      • 7.5.12.3. Product benchmarking
      • 7.5.12.4. Strategic initiatives
    • 7.5.13. United BioSource LLC
      • 7.5.13.1. Overview
      • 7.5.13.2. Financial performance
      • 7.5.13.3. Product benchmarking
      • 7.5.13.4. Strategic initiatives
    • 7.5.14. Mercalis
      • 7.5.14.1. Overview
      • 7.5.14.2. Financial performance
      • 7.5.14.3. Product benchmarking
      • 7.5.14.4. Strategic initiatives
    • 7.5.15. Sciensus
      • 7.5.15.1. Overview
      • 7.5.15.2. Financial performance
      • 7.5.15.3. Product benchmarking
      • 7.5.15.4. Strategic initiatives

List of Tables

  • Table 1 List of secodary sources
  • Table 2 List of abbreviation
  • Table 3 North America pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 4 North America pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 5 North America pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 6 U.S pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 7 U.S pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 8 Canada pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 9 Canada pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 10 Mexico pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 11 Mexico pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 12 Europe pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 13 Europe pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 14 Europe pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 15 Germany pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 16 Germany pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 17 UK pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 18 UK pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 19 France pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 20 France pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 21 Italy pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 22 Italy pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 23 Spain pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 24 Spain pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 25 Denmark pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 26 Denmark pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 27 Sweden pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 28 Sweden pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 29 Norway pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 30 Norway pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 32 Asia Pacific pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 34 China pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 35 China pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 36 Japan pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 37 Japan pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 38 India pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 39 South Korea pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 40 South Korea pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 41 Australia pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 42 Australia pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 43 Thailand pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 44 Thailand pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 45 Latin America pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 46 Latin America pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 47 Latin America pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 48 Brazil pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 49 Brazil pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 50 Argentina pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 51 Argentina pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 52 MEA pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 53 MEA pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 54 MEA pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 55 South Africa pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 56 South Africa pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 57 Saudi Arabia pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 58 Saudi Arabia pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 59 UAE pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 60 UAE pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 61 Kuwait pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 62 Kuwait pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharma HUB and patient access support service market: market outlook
  • Fig. 9 Credentialing software and services competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharma HUB and patient access support service market driver impact
  • Fig. 15 Pharma HUB and patient access support service market restraint impact
  • Fig. 16 Pharma HUB and patient access support service market strategic initiatives analysis
  • Fig. 17 Pharma HUB and patient access support service market: Service type movement analysis
  • Fig. 18 Pharma HUB and patient access support service market: Service type outlook and key takeaways
  • Fig. 19 Program enrollment market estimates and forecast, 2021 - 2033
  • Fig. 20 Order processing market estimates and forecast, 2021 - 2033
  • Fig. 21 Application processing market estimates and forecast, 2021 - 2033
  • Fig. 22 Ease of enrollment (through phone, face, portal, or app) market estimates and forecast, 2021 - 2033
  • Fig. 23 Program data market estimates and forecast, 2021 - 2033
  • Fig. 24 Treatment navigators market estimates and forecast, 2021 - 2033
  • Fig. 25 Process flows and standard operating procedures market estimates and forecast, 2021 - 2033
  • Fig. 26 Program literature and scripts market estimates and forecast, 2021 - 2033
  • Fig. 27 Care team training market estimates and forecast, 2021 - 2033
  • Fig. 28 Systems testing and optimization market estimates and forecast, 2021 - 2033
  • Fig. 29 Reimbursement services/affordability services market estimates and forecast, 2021 - 2033
  • Fig. 30 Clinical educator market estimates and forecast, 2021 - 2033
  • Fig. 31 Coordination of specialty pharmacy/dispensing market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Pharma HUB and patient access support service market: Service delivery type movement analysis
  • Fig. 34 Pharma HUB and patient access support service market: Service delivery type outlook and key takeaways
  • Fig. 35 Integrated services market estimates and forecast, 2021 - 2033
  • Fig. 36 Standalone services market estimates and forecast, 2021 - 2033
  • Fig. 37 Pharma HUB and patient access support service market: Regional movement analysis
  • Fig. 38 Pharma HUB and patient access support service market: Regional outlook and key takeaways
  • Fig. 39 Pharma HUB and patient access support service market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America: SWOT
  • Fig. 46 Europe SWOT
  • Fig. 47 Asia Pacific SWOT
  • Fig. 48 Latin America SWOT
  • Fig. 49 MEA SWOT
  • Fig. 50 North America, by country
  • Fig. 51 North America
  • Fig. 52 North America market estimates and forecasts, 2021 - 2033
  • Fig. 53 U.S.
  • Fig. 54 U.S market estimates and forecasts, 2021 - 2033
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 57 Mexico
  • Fig. 58 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 61 UK
  • Fig. 62 UK market estimates and forecasts, 2021 - 2033
  • Fig. 63 Germany
  • Fig. 64 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 65 France
  • Fig. 66 France market estimates and forecasts, 2021 - 2033
  • Fig. 67 Italy
  • Fig. 68 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 69 Spain
  • Fig. 70 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 71 Denmark
  • Fig. 72 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 73 Sweden
  • Fig. 74 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 75 Norway
  • Fig. 76 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 79 China
  • Fig. 80 China market estimates and forecasts, 2021 - 2033
  • Fig. 81 Japan
  • Fig. 82 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 83 India
  • Fig. 84 India market estimates and forecasts, 2021 - 2033
  • Fig. 85 Thailand
  • Fig. 86 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 87 South Korea
  • Fig. 88 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 89 Australia
  • Fig. 90 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 93 Brazil
  • Fig. 94 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 97 Middle East and Africa
  • Fig. 98 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 107 Market share of key market players- Pharma HUB and patient access support service market